NEDD9 Mediates the FAK/Src Signaling Pathway to Promote the Adhesion of Human Trabecular Meshwork Cells after Dexamethasone Treatment
Rattachement africain : cn, us, ca, hk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The differential gene expression of neural precursor cell expressed developmentally downregulated 9 (NEDD9) in human trabecular meshwork (HTM) cells after dexamethasone (Dex) treatment was confirmed through gene expression profiling. However, the regulatory mechanism of NEDD9 expression in HTM cells remains unknown. In this study, we investigated NEDD9 expression in HTM cells and gained a better understanding of glucocorticoid-induced glaucoma (GIG) pathophysiology. The Gene Expression Omnibus database and GEO2R tool were used to identify differentially expressed genes in the GSE37474 and GSE124114 datasets, and NEDD9 gene expression was found to be upregulated. Human corneoscleral segments and HTM cells were treated with 100 nM Dex or an equal volume of ethanol (0.01%) for 7 days. NEDD9 expression in TM tissues was evaluated by immunohistochemistry, and NEED9 expression in HTM cells was confirmed by RT-qPCR and western blotting. HTM cell adhesive behaviors were assessed with a cell adhesion detection kit. NEDD9 expression was knocked down with short hairpin RNA in HTM cells, and FAK/Src signaling pathway activation was found to be regulated by NEDD9. After 7 days of HTM cell Dex treatment, NEDD9 expression was upregulated to be approximately twice that of control. FAK, Src, phospho-FAK, and phospho-Src expression in Dex-treated HTM cells was markedly increased. Downregulation of NEDD9 expression reduced HTM cell adhesion to the surface of culture wells and simultaneously led to a reduction in FAK, Src, phospho-FAK and phospho-Src expression. NEDD9 expression is upregulated in HTM cells after Dex treatment and promotes HTM cell adhesion. These findings underscore the contribution of NEDD9 overexpression to altered HTM cell adhesion during glucocorticoid therapy and may play a key role in GIG pathological progression. Considering the similarity between GIG and primary open-angle glaucoma (POAG), our findings suggest that targeting NEDD9 may be a new therapeutic strategy for POAG patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Kunming University of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
University of Nebraska–Lincoln pays non établi dans la noticeUniversité ou école supérieure
-
Ministry of Education of the People's Republic of China pays non établi dans la noticeOrganisme public
-
Southwest General Health Center pays non établi dans la noticeÉtablissement de santé
-
North China Electric Power University pays non établi dans la noticeUniversité ou école supérieure
-
Shandong University pays non établi dans la noticeUniversité ou école supérieure
-
Harbin Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Sun Yat-sen University pays non établi dans la noticeUniversité ou école supérieure
-
Chongqing University pays non établi dans la noticeUniversité ou école supérieure
-
Tianjin University pays non établi dans la noticeUniversité ou école supérieure
-
Capital Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Dalian Medical University pays non établi dans la noticeUniversité ou école supérieure
Kunming University of Science and Technology, University of Nebraska–Lincoln et Ministry of Education of the People's Republic of China, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.